SUBSCRIBE
SUBSCRIBE
News   Business

GlaxoSmithKline (JOBS), Vernalis PLC Sign up to $200 Million Cancer Deal

August 6, 2009 | 
1 min read
Bookmark and Share

Reuters -- GlaxoSmithKline Plc, the world's second-largest drugmaker, has signed a deal potentially worth $200 million with British biotech company Vernalis Plc (VER.L) to boost its early-stage research in cancer.
Alliances
GlaxoSmithKline
MORE ON THIS TOPIC
Robot and human hand in retro collage style with halftone. Vector illustration, artificial intelligence concept.
Artificial intelligence
Roche’s Chugai Breaks Into Aging via Potential $1B+ Deal With AI Outfit Gero
July 7, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Social media illustration, business concept, web design
Mergers & acquisitions
Sage’s Search for Lifeline Ran Into Defiant Biogen CEO
July 3, 2025
 · 
3 min read
 · 
Annalee Armstrong
Podcast
CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP
July 2, 2025
 · 
1 min read
 · 
Heather McKenzie
A contemporary artistic collage depicting a hand holding pills, passing them to another hand. The concept of medication and treatment.
Collaboration
Argenx Makes $1.5B+ Play for UNP’s Macrocyclic Peptides Aimed at ‘Undruggable’ Targets
July 1, 2025
 · 
2 min read
 · 
Tristan Manalac